Jun 16, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
New England Journal Of Medicine Publishes Data From Two Phase 3 Studies Of INCIVEK™ (
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2569949" data-attributes="member: 124445"><p>Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the New England Journal of Medicine (NEJM) published data from two Phase 3 studies of INCIVEK™ (telaprevir) tablets, which showed that INCIVEK (in-SEE-veck) combination therapy significantly improved rates of sustained viral response (SVR, or viral cure) in a broad group of people with genotype 1 chronic hepatitis C who were new to treatment and those who were treated previously but not cured (relapsers, partial responders and null responders)... <a href="http://feedads.g.doubleclick.net/~a/lQvUuhjaMKToKsgkqeZF6jrfH6w/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/lQvUuhjaMKToKsgkqeZF6jrfH6w/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p><a href="http://feedads.g.doubleclick.net/~a/lQvUuhjaMKToKsgkqeZF6jrfH6w/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/lQvUuhjaMKToKsgkqeZF6jrfH6w/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p></p><p><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/H02R_qe2418" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/H02R_qe2418/229442.php" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2569949, member: 124445"] Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the New England Journal of Medicine (NEJM) published data from two Phase 3 studies of INCIVEK™ (telaprevir) tablets, which showed that INCIVEK (in-SEE-veck) combination therapy significantly improved rates of sustained viral response (SVR, or viral cure) in a broad group of people with genotype 1 chronic hepatitis C who were new to treatment and those who were treated previously but not cured (relapsers, partial responders and null responders)... [URL="http://feedads.g.doubleclick.net/~a/lQvUuhjaMKToKsgkqeZF6jrfH6w/0/da"][IMG]http://feedads.g.doubleclick.net/~a/lQvUuhjaMKToKsgkqeZF6jrfH6w/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/lQvUuhjaMKToKsgkqeZF6jrfH6w/1/da"][IMG]http://feedads.g.doubleclick.net/~a/lQvUuhjaMKToKsgkqeZF6jrfH6w/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/H02R_qe2418[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/H02R_qe2418/229442.php]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top